Why Organon Is A Top Pick For Income Investors

2025-03-17 22:58:23 ET

Summary

• In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024.
• So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year.
• Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector.
• In this article, you'll learn more about why I believe Organon is an attractive stock for income-oriented investors.

In this article, I will look at Organon (OGN), a pharmaceutical company headquartered in Jersey City that occupies one of the leading positions in the biosimilars and women's health therapeutics markets.

Since early 2025, its share price has been trading sideways despite progress in commercializing Hadlima, a biosimilar to AbbVie's (ABBV) Humira, the acquisition of Dermavant, and maintaining its operating income margin of around 23% despite falling sales of some of its medications [NuvaRing, Zetia, and Atozet], primarily due to increased competition from their generics ....

Read the full article on Seeking Alpha

For further details see: